Skip to main content

9 Result(s)

within J. -E. Frödin Remove this filter

and

  1. No Access

    Article

    Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression

    Cytokines may enhance the effect of therapeutic monoclonal antibodies (mAb). Granulocyte–macrophage colony-stimulating factor (GM-CSF) and interleukin-2 (IL-2) have been shown to increase ADCC levels. GM-CSF m...

    Hjelm A.-L. Skog, P. Wersäll, P. Ragnhammar… in Cancer Immunology, Immunotherapy (2002)

  2. No Access

    Article

    Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma

    Granulocyte/macrophage-colony-stimulating factor (GM-CSF) has previously been indicated to enhance the therapeutic effect of the anti-colorectal carcinoma mAb17-1A as well as to augment in vivo immune effecto...

    A.-L. Hjelm Skog, P. Ragnhammar, J. Fagerberg… in Cancer Immunology, Immunotherapy (1999)

  3. No Access

    Article

    Cytotoxicity of white blood cells activated by granulocyte-colony-stimulating factor, granulocyte/macrophage-colony-stimulating factor and macrophage-colony-stimulating factor against tumor cells in the presence of various monoclonal antibodies

    Unconjugated monoclonal antibodies (mAb) kill tumor cells in vivo by activating immune functions. One of these is ADCC (antibody-dependent cellular cytotoxicity). The efficacy of mAbs might be augmented if the...

    P. Ragnhammar, J. -E. Frödin, P. P. Trotta… in Cancer Immunology, Immunotherapy (1994)

  4. No Access

    Article

    Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1)

    The antitumor effector functions of unconjugated monoclonal antibodies (mAb) in cancer therapy are not fully understood. Direct cytotoxic mechanisms such as antibody-dependent cellular cytotoxicity, complement...

    J. Fagerberg, J. -E. Frödin, P. Ragnhammar, M. Steinitz… in Cancer Immunology, Immunotherapy (1994)

  5. No Access

    Article

    Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma

    Pretreatment with a low dose of cyclophosphamide (CY) has been claimed to inhibit suppressor functions and augment various immune functions. A combination of a low dose of CY, α-interferon (IFN-α) and continuo...

    J.P WersÄll, G. Masucci, A-L Hjelm… in Medical Oncology and Tumor Pharmacotherapy (1993)

  6. No Access

    Article

    Induction of an immune network cascade in cancer patients treated with monoclonal antibodies (ab1)

    The antitumor effector functions of unconjugated monoclonal antibodies in cancer therapy are complex. Direct cytotoxic mechanisms such as antibody-dependent cellular cytotoxicity, complement-dependent cytolysi...

    J. Fagerberg, J-E. Frödin, H. Wigzell, H. Mellstedt in Cancer Immunology, Immunotherapy (1993)

  7. No Access

    Article

    Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor

    Unconjugated monoclonal antibodies (mAb) may induce tumour regression in patients. The mechanisms of action are complex. Antibody-dependent cellular cytotoxicity (ADCC) is considered one of the effector functi...

    P. Ragnhammar, G. Masucci, J -E Frödin, A -L Hjelm… in Cancer Immunology, Immunotherapy (1992)

  8. No Access

    Article

    The clinical use of monoclonal antibodies, MAb 17-1A, in the treatment of patients with metastatic colorectal carcinoma

    Increasing doses of MAb 17-1A (mouse IgG2A) have been given for therapy of patients with metastatic colorectal carcinoma (n = 28). Serum half-life (Tβ1/2l) of MAb 17-1A after a single infusion was about 24 h. A c...

    H. Mellstedt, J. E. Frödin, P. Ragnhammar… in Medical Oncology and Tumor Pharmacotherapy (1989)

  9. No Access

    Chapter and Conference Paper

    Mab 17-1A Used for Therapy of Patients with Metastatic Colorectal Carcinomas

    Tumor cells may express tumor-associated antigens (TAA). However, TAA are also present on normal cells during various stages of differentiation, especially on fetal cells. On normal mature cells, TAA might be ...

    H. Mellstedt, J.-E. Frödin, G. Masucci, C. Lindemalm, C. Wedelin… in Cancer Therapy (1989)